Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20040039030 A1
Publication typeApplication
Application numberUS 10/606,229
Publication dateFeb 26, 2004
Filing dateJun 26, 2003
Priority dateSep 27, 1996
Also published asUS7981909, US8227490, US20100076031, US20110112150, US20110112153, US20110269801, US20120329835
Publication number10606229, 606229, US 2004/0039030 A1, US 2004/039030 A1, US 20040039030 A1, US 20040039030A1, US 2004039030 A1, US 2004039030A1, US-A1-20040039030, US-A1-2004039030, US2004/0039030A1, US2004/039030A1, US20040039030 A1, US20040039030A1, US2004039030 A1, US2004039030A1
InventorsManfred Bohn, Karl Kraemer, Astrid Markus
Original AssigneeHoechst Akeengesellschaft
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
US 20040039030 A1
Abstract
Compounds of the formula (I) are disclosed and are suitable for the treatment of seborrheic dermatitis.
Images(6)
Previous page
Next page
Claims(13)
1. The use of 1-hydroxy-2-pyridones of the formula I
in which R1, R2 and R3, which are identical or different, are a hydrogen atom or alkyl having 1-4 carbon atoms, and
R4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II
where
X is S or O,
Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine,
Z is a single bond or the bivalent radicals O, S, —CR2—(R═H or (C1-C4)-alkyl) or other bivalent radicals having 2-10 carbon and, if appropriate, oxygen and/or sulfur atoms linked in the form of a chain, where—if the radicals contain 2 or more oxygen and/or sulfur atoms—the latter must be separated from one another by at least 2 carbon atoms and where 2 adjacent carbon atoms can also be linked to one another by a double bond and the free valences of the carbon atoms are saturated by H and/or (C1-C4)-alkyl groups,
Ar is an aromatic ring system having up to two rings which can be substituted by up to three radicals from the group consisting of fluorine, chlorine, bromine, methoxy, (C1-C4)-alkyl, trifluoromethyl and trifluoromethoxy, in free or in salt form, for the production of a pharmaceutical for the treatment of seborrheic dermatitis.
2. The use as claimed in claim 1, wherein the compound of the formula I is employed in which Ar is a bicyclic system which is derived from biphenyl, diphenylalkane or diphenyl ether.
3. The use as claimed in claim 1 or 2, wherein the compound of the formula I contains a cyclohexyl radical in the position R4.
4. The use as claimed in one or more of claims 1 to 3, wherein the compound of the formula I contains an octyl radical of the formula —CH2—CH(CH3)—CH2—C(CH3)3 in the position R4.
5. The use as claimed in claim 1, wherein 1-hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxymethyl]-2(1H)pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyridone is employed.
6. The use as claimed in one or more of claims 1 to 5, wherein the pharmaceutical is a hair lotion, shampoo or a cream, ointment or gel preparation.
7. The use as claimed in claim 6, wherein anionic, cationic, nonionic or amphoteric surfactants are employed on their own or as a mixture with other surfactants.
8. The use as claimed in claim 7, wherein the surfactant employed is at least one anionic surfactant on its own or as a mixture with other anionic surfactants and/or amphoteric surfactants.
9. The use as claimed in one or more of claims 1 to 8, wherein the pharmaceutical has a pH of 4.5 to 6.5.
10. A pharmaceutical preparation comprising a 1-hydroxy-2-pyridone of the formula I as claimed in claim 1 and at least one anionic, cationic, nonionic or amphoteric surfactant or a mixture of these surfactants.
11. A pharmaceutical preparation as claimed in claim 10, wherein the surfactant employed is at least one anionic surfactant on its own or as a mixture with other anionic surfactants and/or amphoteric surfactants.
12. A pharmaceutical preparation as claimed in claim 10 or 11, wherein the preparation has a pH of 4.5 to 6.5.
13. A pharmaceutical preparation as claimed in one or more of claims 10 to 12, wherein the 1-hydroxy-2-pyridone of the formula I is employed in a concentration of 0.2% to 10%, preferably of 0.5% to 2%.
Description
  • [0001]
    Seborrheic dermatitis is understood as meaning a disorder of the scalp which differs from simple dandruff by the presence of erythema as a sign of inflammation, by the greater degree of scaling with occasional itching and burning, and by the occurrence of eczematous changes to other body sites. It can occur in the form of patches, but also more frequently affects the whole scalp and often includes, beyond the hairline, the forehead, around the neck and the ears. In severe cases, the scalp can have a secondary infection, and the changes can then exhibit a spongy consistency, vesicle and crust formation and can weep.
  • [0002]
    Seborrheic dermatitis frequently occurs even in infancy and usually remits spontaneously at an age of 8-12 months. The scalp changes consisting of erythema, scaling and occasionally vesicles and crusts in infants can regress spontaneously within a few weeks, intermittently reoccur or persist during the entire childhood. They are frequently combined with a similar. process around the eyelids, nose and ears. Later, the condition usually occurs after puberty and can last for the whole life or even increase in strength. Approximately 1-3% of the population are affected by this illness.
  • [0003]
    It is known that 1-hydroxy-2-pyridones and their salts exhibit activity against normal dandruff which is characterized by a clinically noninflammatory scaling of the scalp occurring in nearly all people (DE 22 34 009).
  • [0004]
    The most promising type of treatment of seborrheic dermatitis until now was the topical application of corticosteroid preparations, but more recently topical therapy with antimycotic substances has gained importance.
  • [0005]
    While corticosteroid preparations display their activity exclusively via an effect on the inflammatory process, the antimycotic substances such as ketoconazole are active exclusively against the yeast fungi of the strain Pityrosporum which is assumed to be the cause of seborrheic dermatitis. The 1-hydroxy-2-pyridones according to the invention, however, combine the properties of both classes of substance in one substance and exhibit both antiinflammatory action and antimycotic activity against Pityrosporum strains.
  • [0006]
    In comparison to ketoconazole, the substances according to the invention —even afteronly a short topical contact time—concentrate rapidly in the skin layers which are relevant for fungal growth and thus contribute to a rapid cure.
  • [0007]
    While ketoconazole is inactive in vitro against gram-positive bacteria (Kinsman et al., J. Med. Microbiol. (1983) 16, No. 2, IV), the hydroxy-pyridones according to the invention exhibit activity against gram-positive and gram-negative aerobic and anaerobic bacteria (Dittmar et al., Arzneim.-Forschung, (1981) 31 (11), No. 8a, pp. 1317-1322). With respect to the treatment of secondarily infected cases, this is an extremely important finding.
  • [0008]
    Compared with ketoconazole, the compounds used according to the invention furthermore have very crucial. advantages with respect to their processing possibilities in pharmaceutical preparations. On account of their solubility in water, alcohols and aqueous-alcoholic solutions, the preparation of hair lotions and transparent gel preparations is possible without problems.
  • [0009]
    The preparations according to the invention can also be employed for the treatment of Pityriasis versicolor, a superficial, noninflammatory skin fungus disorder on the trunk.
  • [0010]
    The invention therefore relates to the use of 1-hydroxy-2-pyridones of the formula I
  • [0011]
    in which R1, R2 and R3, which are identical or different, are a hydrogen atom or alkyl having 1-4 carbon atoms, and
  • [0012]
    R4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II
  • [0013]
    where
  • [0014]
    X is S or O,
  • [0015]
    Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine,
  • [0016]
    Z is a single bond or the bivalent radicals O, S, —CR2—(R═H or (C1-C4)-alkyl) or other bivalent radicals having 2-10 carbon and, if appropriate, oxygen and/or sulfur atoms linked in the form of a chain, where—if the radicals contain 2 or more oxygen and/or sulfur atoms—the latter must be separated from one another by at least 2 carbon atoms and where 2 adjacent carbon atoms can also be linked to one another by a double bond and the free valences of the carbon atoms are saturated by H and/or (C1-C4)-alkyl groups,
  • [0017]
    Ar is an aromatic ring system having up to two rings which can be substituted by up to three radicals from the group consisting of fluorine, chlorine, bromine, methoxy, (C1-C4)-alkyl, trifluoromethyl and trifluoromethoxy, in free or in salt form,
  • [0018]
    for the production of a pharmaceutical for the treatment of seborrheic dermatitis.
  • [0019]
    In the radicals “Z”, the carbon chain members are preferably CH2 groups. If the CH2 groups are substituted by C1-C4-alkyl groups, CH3 and C2H5 are preferred substituents. Exemplary radicals “Z” are:
  • [0020]
    —O—, —S—, —CH2—, —(CH2)m—(m=2-10), —C(CH3)2—, —CH2O—, —OCH2—, —CH2S—, —SCH2—, —SCH(C2H5)—, —CH═CH—CH2O—, —O—CH2—CH═CH—CH2O—, —OCH2—CH2O—, —OCH2—CH2CH2O—, —SCH2CH2CH2S—, —SCH2CH2CH2CH2O—, —SCH2CH2OCH2CH2O —, —SCH2CH2OCH2CH2O —CH2CH2S— or —S—CH2—C(CH3)2—CH2—S—.
  • [0021]
    The radical “S” is a sulfur atom, the radical “O” is an oxygen atom. The term “Ar” denotes phenyl or fused systems such as naphthyl, tetrahydro- naphthyl and indenyl, and also isolated systems as such, which are derived from biphenyl, diphenylalkanes, diphenyl ethers and diphenyl thioethers.
  • [0022]
    In the formula I, the hydrocarbon radial R4 is an alkyl or cyclohexyl radical which can also be bonded to the pyridone ring via a methylene or ethylene group or can contain an endomethyl group. R4 can also be an aromatic radical which, however, is preferably bonded to the pyridone radical via at least one aliphatic carbon atom.
  • [0023]
    Important representatives of the class of compounds characterized by the formula I are:
  • [0024]
    6-[4-(4-chlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone, 6-[4-(2,4-dichlorophenoxy)phenoxymethyl]-1-hydroxy4-methyl-2-pyridone, 6-(biphenyl4-oxymethyl)-1-hydroxy4-methyl-2-pyridone, 6-(4-benzyl-phenoxymethyl)-1-hydroxy4-methyl-2-pyridone, 6-[4-(2,4-dichlorobenzyl-oxy)phenoxymethyl]-1-hydroxy4-methyl-2-pyridone, 6-[4-(4-chloro-phenoxy)phenoxymethyl]-1-hydroxy-3,4-dimethyl-2-pyridone, 6-[4-(2,4-dichlorobenzyl)phenoxymethyl]-1-hydroxy-3,4-dimethyl-2-pyridone, 6-[4-cinnamyloxy)phenoxymethyl]-1-hydroxy4-methyl-2-pyridone, 1-hydroxy4-methyl-6-[4-(4-trifluoromethylphenoxy)phenoxymethyl]-2-pyridone, 1hydroxy-4-methyl-6-cyclohexyl-2-pyridone, 1-hydroxy4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone, 1-hydroxy4-methyl-6-n-hexyl-, -6-iso-hexyl-, -6-n-heptyl- or -6-isoheptyl-2-pyridone, 1-hydroxy4-methyl-6-octyl- or -6-isooctyl-2-pyridone, in particular 1-hydroxy4-methyl-6-cyclohexyl-methyl- or -6-cyclohexylethyl-2-pyridone, where the cyclohexyl radical can in each case also carry a methyl radical, 1-hydroxy4-methyl-6-(2-bicyclo-[2,2,1]heptyl)-2-pyridone, 1-hydroxy-3,4-dimethyl-6-benzyl- or -6-dimethyl-benzyl-2-pyridone or 1-hydroxy4-methyl-6-(β-phenylethyl)-2-pyridone.
  • [0025]
    The term “saturated” in this case designates those radicals which contain no aliphatic multiple bonds, i.e. no ethylenic or acetylenic bonds.
  • [0026]
    The abovementioned compounds of the formula I can be employed either in free form or as salts, use in free form is preferred.
  • [0027]
    If organic bases are used, poorly volatile bases are preferably employed, for example low molecular weight alkanolamines such as ethanolamine, diethanolamine, N-ethylethanolamine, N-methyidiethanolamine, triethanol-amine, diethylaminoethanol, 2-amino-2-methyl-n-propanol, dimethylamino-propanol, 2-amino-2-methylpropanediol, triisopropanolamine. Further poorly volatile bases which may be mentioned are, for example, ethylenediamine, hexamethylenediamine, morpholine, piperidine, piperazine, cyclohexylamine, tributylamine, dodecylamine, N,N-dimethyldodecylamine, stearylamine, oleylamine, benzylamine, dibenzylamine, N-ethylbenzylamine, dimethylstearylamine, N-methylmorpholine, N-methylpiperazine, 4-methylcyclohexylamine, N-hydroxyethylmorpholine. The salts of quaternary ammonium hydroxides such as trimethylbenzylammonium hydroxide, tetramethylammonium hydroxide or tetraethylammonium hydroxide can also be used, furthermore guanidine and its derivatives, in particular its alkylation products. However, it is also possible to employ as salt-forming agents, for example, low molecular weight alkylamines such as methylamine, ethylamine or triethylamine. Suitable salts for the compounds to be employed according to the invention are also those with inorganic cations, for example alkali metal salts, in particular sodium, potassium or ammonium salts, alkaline earth metal salts such as, in particular, the magnesium or calcium salts, as well as salts with bi- or tetravalent cations, for example the zinc, aluminum or zirconium salt.
  • [0028]
    The active compounds to be employed in the preparations of the compound of the formula I can be prepared, for example, according to processes given in U.S. Pat. No. 2,540,218.
  • [0029]
    For the use according to the invention of the compounds mentioned, liquid to semisolid pharmaceutical preparations, in particular hair lotions, shampoos, liquid soaps, as well as cream, ointment and gel preparations, are suitable.
  • [0030]
    In this case, these are always preparations which, depending on their actual intended use, are applied to the skin and/or to the scalp for a shorter or longer time. Due to the addition of the compounds according to the invention, an effective treatment of the seborrheic dermatitis is brought about.
  • [0031]
    If the preparations according to the invention are present as shampoo, they can be in clear liquid or opaque liquid form, in cream form or even gelatinous. The surfactants on which these shampoos are based can be of anionic, cationic, nonionic or amphoteric nature and can also be present as a combination of these substances.
  • [0032]
    Preferably, however, anionic surfactants are employed on their own or as a mixture with other anionic surfactants as base surfactants - if appropriate with addition of amphoteric surfactants as cosurfactant.
  • [0033]
    As the sole detergent substances, amphoteric surfactants are virtually insignificant, since their foaming behavior, thickenability and partly also skin and eye mucous membrane tolerability are only moderate. In combination with various anionic surfactants, however, precisely these properties are synergistically improved. This explains the relatively great importance of the amphoteric surfactants for the optimization of anionic shampoo bases.
  • [0034]
    Nonionic surfactants can also be employed as cosurfactants.
  • [0035]
    Examples of anionic detergent substances of this type which may be mentioned are: (C10-C20)-alkyl- and -alkylenecarboxylates, alkyl ether carboxylates, fatty alcohol sulfates, fatty alcohol ether sulfates, alkylol-amide sulfates and sulfonates, fatty acid alkylamide polyglycol ether sulfates, alkanesulfonates and hydroxyalkanesulfonates, olefinsulfonates, acyl esters of isothionates, α-sulfofatty acid esters, alkylbenzosulfonates, alkylphenol glycol ether sulfonates, sulfosuccinates, sulfosuccinic acid hemiesters and diesters, fatty alcohol ether phosphates, protein-fatty acid condensation products, alkylmonoglyceride sulfates and sulfonates, alkylglyceride ether sulfonates, fatty acid methyltaurides, fatty acid sarcosinates or sulforicinoleates. These compounds and their mixtures are used in the form of their water-soluble or water-dispersible salts, for example the sodium, potassium, magnesium, ammonium, mono-, di- and triethanolammonium as well as analogous alkylolammonium salts.
  • [0036]
    Examples of amphoteric surfactants which can be added to the shampoos are: N-((C12-C18)-alkyl)-β-aminopropionates and N-((C12-C18)-alkyl)-β-iminodipropionates as alkali metal and mono-, di- and trialkylol-ammonium salts; N-acylamidoalkyl-N,N-dimethylacetobetaine, preferably N-((C8-C18)-acyl)amidopropyl-N,N-dimethylacetobetaine; (C12-C18)-alkyl-dimethylsulfopropylbetaine; amphoteric surfactants based on imidazoline (trade name: Miranol®, Steinapon®), preferably the sodium salt of 1-(β-carboxymethyloxyethyl)-1-(carboxymethyl)-2-laurylimidazolinium; amine oxides, e.g. (C12-C18)-alkyldimethylamine oxide or fatty acid amidoalkyldimethylamine oxide.
  • [0037]
    Suitable nonionic surfactants which can be employed as detergent substances are, for example: fatty alcohol ethoxylates (alkyl polyethylene glycols); alkylphenol polyethylene glycols; alkylmercaptan. polyethylene glycols; fatty amine ethoxylates (alkylamino polyethylene glycols); fatty acid ethoxylates (acyl polyethylene glycols), polypropylene glycol ethoxylates (Pluronic®); fatty acid alkylolamides (fatty acid amide polyethylene glycols); sucrose esters; alkyl polyglucosides; sorbitol esters and polyglycol ether.
  • [0038]
    Suitable cationic surfactants are, for example, quaternary ammonium salts such as di-((C10-C24)-alkyl)dimethylammonium chloride or bromide, preferably di-((C12-C18)-alkyl)dimethylammonium choride or bromide; (C10-C24)-alkyldimethylethylammonium chloride or bromide; (C10-C24)-alkyltrimethylammonium chloride or bromide, preferably cetyltrimethyl-ammonium chloride or bromide and (C20-C22)-alkyltrimethylammonium chloride or bromide; (C10-C24)-alkyldimethylbenzylammonium chloride or bromide; preferably (C12-C18)-alkyldimethylbenzylammonium chloride; N-((C10-C18)-alkyl)pyridinium chloride or bromide, preferably N-((C12-C16)-alkyl)pyridinium chloride or bromide; N-((C10-C18)-alkyl)isoquinolinium chloride, bromide or monoalkylsulfate; N-((C12-C18)-alkylolaminoformyl-methyl)pyridinium chloride; N-((C12-C18)-alkyl)-N-methylmorpholinium chloride, bromide or monoalkylsulfate, N-((C12-C18)-alkyl)-N-ethyl-morpholinium chloride, bromide or monoalkylsulfate; (C16-C18)-alkyl-pentaoxethylammonium chloride; diisobutylphenoxyethoxyethyldimethyl-benzylammonium chloride; salts of N,N-diethylaminoethylstearylamide and -oleylamide with hydrochloric acid, acetic acid, lactic acid, citric acid, phosphoric acid; N-acylamidoethyl-N,N-diethyl-N-methylammonium chloride, bromide or monoalkylsulfate and N-acylamidoethyl-N,N-diethyl-N-benzylammonium chloride, bromide or monoalkylsulfate, where acyl is preferably stearyl or oleyl.
  • [0039]
    The preparations according to the invention can additionally contain further additives, e.g. aromatic substances, cblorants, opacifiers and pearl luster agents, for example esters of fatty acids and polyols, magnesium and zinc salts of fatty acids, dispersions based on copolymers, thickeners such as sodium, potassium or ammonium chloride, sodium sulfate, fatty acid alkylolamides, cellulose derivatives of natural gums, collagen hydrolyzates, furthermore fats, oils, fatty alcohols, silicones, substances having a keratolytic and keratoplastic action. for example sulfur, salicylic acid or enzymes.
  • [0040]
    The shampoos are prepared in a manner known per se by mixing together of the individual components and a further processing—if necessary —suited to the particular type of preparation. Some of these various possible preparations are described by way of example in the working examples.
  • [0041]
    The preparations according to the invention can also be present in the form of aqueous and aqueous-alcoholic hair lotions, and also those in gel form and in aerosol form as spray or foam. Alcohols employed are preferably ethanol and isopropyl alcohol.
  • [0042]
    Further preparations which may be mentioned in which the 1-hydroxy-2-pyridones can be used according to the invention are, for example, cream and ointment preparations, products which are primarily used for the treatment of hairless head and body parts.
  • [0043]
    The preparation of all these preparations is also carried out—as already mentioned in the case of shampoo—in a manner known per se with addition of the active compound employed according to the invention. Of the abovementioned 1-hydroxy-2-pyridones, the preparations according to the invention can contain one compound or even several in combination.
  • [0044]
    The pH of the preparations is in the skin-physiological range of approximately pH 4.5 to 6.5. Whereas, when using the compounds in salt form, the adjustment of the pH range mentioned has to be carried out using organic acids, this measure is not necessary when using the free compounds.
  • [0045]
    In the preparations according to the invention, the active compounds is incorporated in amounts which are customarily between approximately 0.05 and approximately 10%. Within this range, the concentrations of the specific preparations depend on their intended use. Certain preparation forms such as concentrates, which are to be diluted before use, can have considerably higher concentrations.
  • [0046]
    If they are preparations which remain on the skin and on the scalp, for example gel preparations, ointments, creams or hair lotions, lower concentrations will be employed, for example from about 0.05% to about 1%, preferably from 0.1 to 0.5%. In higher concentrations, they will expediently be used when they are preparations which, optionally after dilution, only act on the scalp for a short time, for example shampoos or liquid soaps. In these cases, for example, concentrations of approximately 0.2 to approxi- mately 10%, preferably from approximately 0.5% to approximately 2%, can be expedient.
  • [0047]
    The following quantitative data relate to the weight, if not stated otherwise.
  • EXAMPLE 1
  • [0048]
    A preparation according to the invention has the following composition:
  • [0049]
    Shampoo (based on anionic detergent substances)
    1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone  1.00%
    Sodium lauryl diglycol ether sulfate (27% strength solution) 40.00%
    Disodium lauryl polyglycol ether sulfosuccinate (33% strength 10.00%
    solution)
    Sodium chloride  2.50%
    Water 46.50%
  • EXAMPLE 2
  • [0050]
    A preparation according to the invention has the following composition:
  • [0051]
    Shampoo (based on anionic detergent substance with amphoteric surfactant as cosurfactant)
    1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone  1.00%
    Sodium lauryl diglycol ether sulfate (27% strength solution) 36.00%
    Cocamidopropylbetaine (30% strength solution)  6.00%
    Sodium chloride  3.30%
    Water 53.70%
  • EXAMPLE 3
  • [0052]
    A preparation according to the invention has the following composition:
  • [0053]
    Shampoo (based on anionic detergent substance with nonionic surfactant as cosurfactant)
    1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone  1.50%
    Sodium lauryl diglycol ether sulfate (27% strength solution) 30.00%
    Lauryl alcohol polyglucoside  8.00%
    Sodium chloride  2.00%
    Water 58.50%
  • EXAMPLE 4
  • [0054]
    A preparation according to the invention has the following composition:
  • [0055]
    Liquid soap
    1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone  1.00%
    Sodium lauryl diglycol ether sulfate (27% strength solution) 35.00%
    Cocamidopolyglycol ether sulfate magnesium salt (30% strength  8.00%
    solution)
    Cocamidopropylbetaine (30% strength solution) 10.00%
    Lauryl alcohol glycol ether  2.00%
    Sodium chloride  2.00%
    Water 42.00%
  • EXAMPLE 5
  • [0056]
    A preparation according to the invention has the following composition:
  • [0057]
    Hair lotion
    1-Hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxymethyl]-  0.05%
    2(1H)pyridone
    2-Propanol 60.00%
    Water 39.95%
  • EXAMPLE 6
  • [0058]
    A preparation according to the invention has the following composition:
  • [0059]
    Gel preparation
    1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone  0.75%
    2-Propanol 15.00%
    2-Octyldodecanol  7.50%
    Carbomer 4,000,000  0.50%
    Polysorbate 60  1.50%
    Sodium hydroxide  0.18%
    Water 74.57%
  • EXAMPLE 7
  • [0060]
    A preparation according to the invention has the following composition:
  • [0061]
    Cream preparation
    1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)-pyridone,  1.00%
    aminoethatnol salt 1:1
    2-Octyldodecanol  7.50%
    Liquid paraffin  7.50%
    Stearyl alcohol  7.50%
    Cetyl alcohol  7.50%
    Polysorbate 60  3.00%
    Sorbitan monostearate  2.00%
    Lactic acid, 90% strength  0.51%
    Water 63.49%
  • EXAMPLE 8
  • [0062]
    In a clinical study with a total of 180 patients, it was possible to show that the symptoms of seborrheic dermatitis of the scalp (severe scaling, inflammation, itching) can be effectively treated by a 1-2×weekly treatment with a 1% strength ciclopirox shampoo preparation over a period of 4 weeks.
  • EXAMPLE 9
  • [0063]
    In a clinical study, it was possible to successfully treat 180 patients with seborrheic dermatitis of the scalp, of the face and of the upper body by application of a 0.77% strength ciclopirox gel preparation over a period of 4 weeks.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3883545 *Dec 22, 1972May 13, 1975Hoechst AgCertain 1-hydroxy-2-pyridones
US3968118 *Aug 30, 1974Jul 6, 1976Hoechst AktiengesellschaftProcess for the manufacture of 1-hydroxy-2-pyridones
US4185106 *Aug 15, 1975Jan 22, 1980Hoechst AktiengesellschaftPyridones as antidandruff agents
US4699924 *Jan 23, 1984Oct 13, 1987Lever Brothers CompanySkin treatment composition
US4711775 *Dec 4, 1984Dec 8, 1987Hoechst AktiengesellschaftCosmetic compositions
US4797109 *Feb 25, 1988Jan 10, 1989Methode Electronics, Inc.Coiled wire interconnector
US4797409 *Apr 16, 1987Jan 10, 1989Hoechst Aktiengesellschaft1-hydroxy-2-pyridones, a process for their preparation, and medicaments which contain them, and intermediates formed in the preparation of the 1-hydroxy-2-pyridones
US4957730 *Dec 17, 1986Sep 18, 1990Hoechst AktiengesellschaftAntimycotic nail varnish
US5066484 *Apr 30, 1990Nov 19, 1991Revlon, Inc.Nail enamels containing glyceryl, glycol or citrate esters
US5071639 *Mar 22, 1989Dec 10, 1991Shiseido Company Ltd.Nail cosmetic composition
US5120530 *Feb 22, 1990Jun 9, 1992Hoffmann-La Roche Inc.Antimicotic nail varnish containing amorolfine in quaternary ammonium acrylic copolymer
US5132107 *Sep 28, 1990Jul 21, 1992Lange Bouke JTwo-phase cleansing, conditioning and medicinal treatment shampoo
US5264206 *Jun 14, 1988Nov 23, 1993Hoechst AktiengesellschaftNail lacquer with antimycotic activity, and a process for the preparation thereof
US5346692 *Apr 8, 1993Sep 13, 1994Roehm Pharma GmbhNail lacquer for the treatment of onychomycosis
US5356907 *Oct 1, 1992Oct 18, 1994Roussel Uclaf1-cycloalkylpyridones as analgesics
US5395843 *Apr 30, 1993Mar 7, 1995Roussel-UclafPyridones
US5494658 *Oct 3, 1994Feb 27, 1996Hoechst AktiengesellschaftAntidandruff agents and cosmetic preparations
US5495658 *Jul 13, 1994Mar 5, 1996Sanden Corp.Method of making cylindrical ferromagnetic body and cover assembly for rotor of DC motor
US5510100 *Jun 10, 1994Apr 23, 1996L'orealOil-in-water emulsions containing an auto-emulsifiable composition based on a fatty alcohol and on an alkyl polyoside and a co-emulsifying agent
US5559130 *Nov 29, 1994Sep 24, 1996Roussel UclafPyrrolidinyl pyridones for treating pain
US5603939 *Nov 12, 1993Feb 18, 1997L'orealFilm-forming cosmetic composition based on a chlorinated graft copolymer resulting from the grafting of a chlorinated polyolefin and acrylic, styrene and/or vinyl type unsaturated monomers
US5609854 *Jun 6, 1995Mar 11, 1997Elizabeth Arden Company, Division Of Conopco, Inc.Thickened and stabilized cosmetic emulsion compositions
US5612327 *Sep 1, 1994Mar 18, 1997Teijin Limited1α,24-(OH)2 -cholecalciferol emulsion composition and method for treating psoriasis
US5650145 *May 5, 1995Jul 22, 1997L'orealDermatological/cosmetic compositions comprising antifungal and antibacterial compounds and reduction of hair loss therewith
US5675013 *Sep 30, 1994Oct 7, 1997Olin Corporation1-hydroxy-6-substituted pyridine-2-ones and 1-hydroxy-6-substituted pyridine-2-thiones for biocidal use
US5683681 *Apr 6, 1995Nov 4, 1997L'orealCosmetic compositions for application to the nail
US5753600 *Nov 14, 1994May 19, 1998Kao CorporationLiquid detergent composition
US5756108 *Nov 9, 1995May 26, 1998L'orealOily phase in an aqueous phase dispersion stabilized by cubic gel particles and method of making
US5814322 *Jul 11, 1995Sep 29, 1998L'orealGelled cosmetic and/or dermatological composition which is rich in solvent and which contains hollow particles, and its applications
US5866105 *Jun 6, 1995Feb 2, 1999Novartis AgPharmaceutical composition
US6162420 *May 3, 1996Dec 19, 2000Hoechst AktiengesellschaftUse of glyceryl triacetate for treating onychomycoses
US6455551 *Nov 21, 1996Sep 24, 2002Aventis Pharma Deutschland GmbhUse of 1-hydroxy-2-pyridones for treating mucosa diseases which are difficult to treat
US6469033 *Sep 16, 1997Oct 22, 2002Aventis Pharma Deutschland GmbhUse of 1-hydroxy-2-pyridones for the treatment of skin diseases
US6514490 *Jan 26, 2001Feb 4, 2003Janssen Pharmaceutica N.V.Compositions containing an antifungal and a cationic agent
US20030086881 *Dec 16, 2002May 8, 2003Aventis Pharma Deutschland GmbhAntiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails
US20040081677 *Oct 23, 2003Apr 29, 2004Aventis Pharma Deutschland Gmbh.Antimycotic gel having high active compound release
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7026337Oct 23, 2003Apr 11, 2006Aventis Pharma Deutschland GmbhAntimycotic gel having high active compound release
US7740875Oct 8, 2004Jun 22, 2010Mediquest Therapeutics, Inc.Organo-gel formulations for therapeutic applications
US7776349Oct 11, 2005Aug 17, 2010Mediquest Therapeutics, Inc.Organo-gel formulations for therapeutic applications
US7981909Jan 31, 2011Jul 19, 2011Medicis Pharmaceutical CorporationUse of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
US8609637Dec 2, 2011Dec 17, 2013The University Of KansasProdrugs of 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-(1H)-one and derivatives thereof
US9243014Oct 21, 2013Jan 26, 2016The University Of KansasMethod of treatment with prodrugs of 6-cyclohexyl-1-hydroxy-4-methylpyridin in-2-1H-one and derivatives thereof
US20040081677 *Oct 23, 2003Apr 29, 2004Aventis Pharma Deutschland Gmbh.Antimycotic gel having high active compound release
US20060078577 *Oct 8, 2004Apr 13, 2006Mediquest Therapeutics, Inc.Organo-gel formulations for therapeutic applications
US20060078579 *Feb 28, 2005Apr 13, 2006Mediquest Therapeutics, Inc.Organo-gel formulations for therapeutic applications
US20060078580 *Jun 13, 2005Apr 13, 2006Mediquest Therapeutics, Inc.Organo-gel formulations for therapeutic applications
US20060121118 *Jan 31, 2006Jun 8, 2006Aventis Pharma Deutschland GmbhAntimycotic gel having high active compound release
US20110112153 *Jan 31, 2011May 12, 2011Manfred BohnUse of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
WO2012075396A3 *Dec 2, 2011Dec 27, 2012The University Of KansasProdrugs of 6-cyclohexyl-1-hydroxy-4- methylpyridin-2(1h)-one and derivatives thereof
Classifications
U.S. Classification514/345
International ClassificationA61K8/49, A61Q5/02, A61Q5/00, A61Q19/00, A61K31/4412
Cooperative ClassificationA61Q5/02, Y10S514/861, Y10S514/881, A61K8/4926, Y10S514/863, Y10S514/852, A61K31/4412, Y10S514/864, A61Q5/006, A61Q19/00
European ClassificationA61K8/49C4, A61K31/4412, A61Q19/00, A61Q5/02, A61Q5/00F
Legal Events
DateCodeEventDescription
Jul 18, 2006ASAssignment
Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, GERMANY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOECHST AKTIENGESELLSCHAFT;REEL/FRAME:017952/0728
Effective date: 20020304
Owner name: HOECHST AKTIENGESELLSCHAFT, GERMANY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOHN, MANFRED;KRAEMER, KARL THEODOR;MARKUS, ASTRID;REEL/FRAME:017952/0637;SIGNING DATES FROM 19980515 TO 19980520
Jul 19, 2006ASAssignment
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY
Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:017946/0877
Effective date: 20050901
Jan 5, 2009ASAssignment
Owner name: MEDICIS PHARMACEUTICAL CORPORATION, ARIZONA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SANOFI-AVENTIS DEUTSCHLAND GMBH;REEL/FRAME:022052/0292
Effective date: 20081101